PTPRF and neoplasm: Consistently, the gemcitabine + SOM230-LAR bi-therapy-induced tumour growth reduction was associated with a dramatic increase in cell apoptosis (cleaved caspase-3 and TUNEL), and an inhibition of cell proliferation (Ki67) (Fig5E–H, Supplementary Figs S7A–B, D and S8D–E) in the three tumour mouse models was tested.